N. Jim Rhodes, Pharm.D., M.S., BCPS

Associate Professor
Downers Grove, IL

Home / Academics / Our Faculty / N. Jim Rhodes, Pharm.D., M.S., BCPS


Dr. N. Jim Rhodes, PharmD, MSc, BCPS AQ-Infectious Diseases completed his Doctor of Pharmacy degree at the University of Florida and a Master of Science in Clinical Investigations at Northwestern University. He also completed four years of post-graduate training including a pharmacy practice residency, a specialty infectious diseases residency, and a two-year fellowship in Infectious Diseases Pharmacotherapy focusing on clinical outcomes and pharmacometrics. Dr. Rhodes is currently an Associate Professor at Midwestern University where he serves as a clinical and didactic instructor in infectious diseases therapeutics and clinical pharmacokinetics. In 2018, he joined the Midwestern University Pharmacometrics Center of Excellence. In 2020, he released a user interface for the Optimal Data Analysis non-parametric machine learning algorithm which is available in R. He is engaged in clinical-translational research at Midwestern University and Northwestern Memorial Hospital, where he practices clinically in acute-care infectious diseases and antimicrobial stewardship. He actively participates in infectious diseases organizations, publication peer-reviews, extramural funding reviews, and continuing education content for clinical pharmacy specialties.

Associate Professor

Downers Grove, IL

College of Pharmacy
Downers Grove Campus

Pharmacy Practice


Call My


Send Me
a Message



| 2018 | AQ-ID
Northwestern University | 2015 | M.SC
University of Florida | 2011 | Pharm.D.

Courses Taught

Courses taught:

PHARD 1561: Pharmacy Practice Development and Evaluation I (Spring PS-1)

PHIDD 1607: Integrated Sequence 7 (Winter PS-2)

PHIDD 1608 : Integrated Sequence 8  (Spring PS-2)

PPRAD 1316: Advanced Infectious Diseases Elective (Summer PS-2)

PPRAD 1301: Introduction to Research Elective (rolling)


Dr. Rhodes’s interests include anti-infective pharmacokinetics and pharmacodynamics, clinical outcomes, and predictive modeling. His research is primarily focused on clarifying the antimicrobial-exposure-response profiles in clinical and translational models. His research program also seeks to evaluate how contemporary antimicrobial utilization influences resistance and clinical outcomes. He is actively involved in mentoring post-doctoral PharmD residents and fellows. For more information about the Infectious Diseases Pharmacotherapy Fellowship, see the following link.


Selected publications from over 90 peer reviewed manuscripts:

  1. Rhodes NJ, Rohani R, Yarnold PR, Pawlowski AE, Malczynski M, Qi C, Sutton SH, Zembower TR, Wunderink RG. Machine Learning To Stratify Methicillin-Resistant Staphylococcus aureus Risk among Hospitalized Patients with Community-Acquired Pneumonia. Antimicrob Agents Chemother. 2023 Jan 24;67(1):e0102322. doi: 10.1128/aac.01023-22. Epub 2022 Dec 6. PMID: 36472425; PMCID: PMC9872682.

  2. Rohani R, Scheetz MH, Donnelly HK, Donayre A, Kang M, Diaz E, Dedicatoria K, Hauser AR, Ozer EA, Nozick S, Qi C, Pawlowski AE, Neely MN, Misharin AV, Wunderink RG, Rhodes NJ; NU SCRIPT Study investigators. Individual target pharmacokinetic/pharmacodynamic attainment rates among meropenem-treated patients admitted to the ICU with hospital-acquired pneumonia. J Antimicrob Chemother. 2022 Oct 28;77(11):2956-2959. doi: 10.1093/jac/dkac245. PMID: 35869779; PMCID: PMC10205601.

  3. Wu EL, Al-Heeti O, Hoff BM, Williams JL, Krueger KM, Santoiemma PP, Rhodes NJ. Role of Therapeutic Drug Monitoring in the Treatment of Persistent Mycobacterium abscessus Central Nervous System Infection: A Case Report and Review of the Literature. Open Forum Infect Dis. 2022 Jul 30;9(8):ofac392. doi: 10.1093/ofid/ofac392. PMID: 35983263; PMCID: PMC9379816.

  4. O'Donnell JN, Putra V, Maring BL, Ozer EA, Belfiore GM, Rhodes NJ. Effect of omadacycline alone and in combination with meropenem against carbapenem-resistant Acinetobacter baumannii isolates. J Glob Antimicrob Resist. 2022. Jun;29:147-149. doi: 10.1016/j.jgar.2022.03.006. Epub 2022 Mar 15. PMID: 35301177.

  5. Leung E, Crass RL, Jorgensen SCJ, Raybardhan S, Langford BJ, Moore WJ, Rhodes NJ. Pharmacokinetic/Pharmacodynamic Considerations of Alternate Dosing Strategies of Tocilizumab in COVID-19. Clin Pharmacokinet. 2022 Feb;61(2):155-165. doi: 10.1007/s40262-021-01092-0. Epub 2021 Dec 11. PMID: 34894345; PMCID: PMC8665708.

  6. Rohani R, Hoff B, Jain M, Philbrick A, Salama S, Cullina JF, Rhodes NJ. Defining the Importance of Age-Related Changes in Drug Clearance to Optimizing Aminoglycoside Dosing Regimens for Adult Patients with Cystic Fibrosis. Eur J Drug Metab Pharmacokinet. 2022 Mar;47(2):199-209. doi: 10.1007/s13318-021-00734-9. Epub 2021 Dec 9. PMID: 34882292.

  7. O'Donnell JN, Rhodes NJ, Miglis CM, Zembower TR, Qi C, Hoff BM, Barr VO, Gilbert EM, Bolon MK, Malczynski M, Gener J, Tran C, Catovic L, Postelnick MJ, Sutton SH, Scheetz MH. Impact of early antimicrobial stewardship intervention in patients with positive blood cultures: results from a randomized comparative study. Int J Antimicrob Agents. 2022 Feb;59(2):106490. doi: 
    10.1016/j.ijantimicag.2021.106490. Epub 2021 Dec 3. PMID: 34871745.

  8. Rhodes NJ, Jozefczyk CC, Moore WJ, Yarnold PR, Harkabuz K, Maxwell R, Sutton SH, Silkaitis C, Qi C, Wunderink RG, Zembower TR. Characterizing Risk Factors for Clostridioides difficile Infection among Hospitalized Patients with
    Community-Acquired Pneumonia. Antimicrob Agents Chemother. 2021 Jun 17;65(7):e0041721. doi: 10.1128/AAC.00417-21. Epub 2021 Jun 17. PMID: 33875439; PMCID: PMC8373232.

  9. Rhodes NJ, Dairem A, Moore WJ, Shah A, Postelnick MJ, Badowski ME, Michienzi SM, Borkowski JL, Polisetty RS, Fong K, Spivak ES, Beardsley JR, Hale CM, Pallotta AM, Srinivas P, Schulz LT. Multicenter point prevalence evaluation of the utilization and safety of drug therapies for COVID-19 at the onset of the pandemic timeline in the United States. Am J Health Syst Pharm. 2021 Mar 18;78(7):568-577. doi: 10.1093/ajhp/zxaa426. PMID: 33537767; PMCID: PMC7929420.

  10. Avedissian SN, Rohani R, Bradley J, Le J, Rhodes NJ. Optimizing Aminoglycoside Dosing Regimens for Critically Ill Pediatric Patients with Augmented Renal Clearance: a Convergence of Parametric and Nonparametric Population Approaches. Antimicrob Agents Chemother. 2021 Mar 18;65(4):e02629-20. doi: 10.1128/AAC.02629-20. PMID: 33526481; PMCID: PMC8097479.

  11. Liu J, Tong SYC, Davis JS, Rhodes NJ, Scheetz MH; CAMERA2 Study Group. Vancomycin Exposure and Acute Kidney Injury Outcome: A Snapshot From the CAMERA2 Study. Open Forum Infect Dis. 2020 Nov 4;7(12):ofaa538. doi: 10.1093/ofid/ofaa538. PMID: 33335938; PMCID: PMC7731530.

  12. Hoff BM, Scheetz MH, Jain M, Cullina JF, Rhodes NJ. Exploring the Relationship between FEV1 Loss and Recovery and Aminoglycoside Pharmacokinetics in Adult Patients with Cystic Fibrosis: Implications for Clinical Dosing Strategies. Pharmacotherapy. 2020 Jun;40(6):584-591. doi: 10.1002/phar.2399. Epub 2020 May 5. PMID: 32259317.

  13. Mahmoud A, Shah A, Nutley K, Nicolau DP, Sutherland C, Jain M, Scheetz MH, Rhodes NJ. Clinical pharmacokinetics of ceftolozane and tazobactam in an obese patient receiving continuous venovenous haemodiafiltration: A patient case and literature review. J Glob Antimicrob Resist. 2020 Jun;21:83-85. doi: 10.1016/j.jgar.2020.03.003. Epub 2020 Mar 19. PMID: 32200125.

  14. Rhodes NJ, Wagner JL, Davis SL, Bosso JA, Goff DA, Rybak MJ, Scheetz MH; MAD-ID Research Network. Trends in and Predictors of Carbapenem Consumption across North American Hospitals: Results from a Multicenter Survey by the MAD-ID Research Network. Antimicrob Agents Chemother. 2019 Jun 24;63(7):e00327-19. doi: 10.1128/AAC.00327-19. PMID: 31061154; PMCID: PMC6591614.
  15. Rhodes NJ, Liu J, O'Donnell JN, Dulhunty JM, Abdul-Aziz MH, Berko PY, Nadler B, Lipman J, Roberts JA. Prolonged Infusion Piperacillin-Tazobactam Decreases Mortality and Improves Outcomes in Severely Ill Patients: Results of a Systematic Review and Meta-Analysis. Crit Care Med. 2018 Feb;46(2):236-243. doi: 10.1097/CCM.0000000000002836. PMID: 29116995.

Complete List of Published Work in My Bibliography:


Organizations, Committees, and Service

American Association of Colleges of Pharmacy (AACP)                    (July 2012 – Present)


American College of Clinical Pharmacy (ACCP)                                (July 2012 – Present)

            Infectious Diseases (ID) Practice and Research Network      (July 2012 – Present)


American Society for Microbiology (ASM)                                          (Aug 2013 – Present)


Society of Infectious Diseases Pharmacists (SIDP)                           (Sept 2012 – Present)

Research Committee                                                                         (Sept 2014-2018, 2023-)

Recognitions Committee                                                                    (Oct 2018 – Sept 2021)


Title: Assessment of MODS and Personalized Exposures of Antibiotics (AMPLE)
Award: R01-HD103755
Period: 9/2021-8/2026
Role: Co-I (Scheetz/Downes MPIs)

Title: Systems-based pharmacologic modelling to elucidate beta-lactam clinical pharmacodynamics and define optimal dosing regimens in severe pneumonia.
Award: R01-AI158530
Period: 07/2022-6/2027
Role: PI



SIDP Young Investigator Award 2019: Awarded October 1, 2019 in recognition of research accomplishments of young investigators who show research promise in infectious diseases.

MWU CCP New Preceptor Excellence Award 2018-2019: Awarded May 22, 2019 in recognition of excellence in precepting Midwestern University CCP students on rotation.